Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients
Recruiting · NCT05912816 · Registry updated 2025-12-09Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients | HER-2 ADC; Kidney Preservation; PD-1antibody; Upper Urinary Tract Urothelial Carcinoma | Recruiting | Phase 2 | 2025-12-09 | NCT05912816 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Peking University First Hospital | 225 |
| RenJi Hospital | 264 |
| Tianjin Medical University Second Hospital | 50 |
| West China Hospital | 359 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ethics Committee of Shanghai Renji Hospital | Shanghai | China | 2 |